Herbie Newell is Professor of Cancer Therapeutics at Newcastle University, and was Director of Translational Research at Cancer Research UK from 2006 to 2009, and interim Executive Director of Clinical and Translational Research in 2007/8. He was the founding Scientific Director of the Northern Institute for Cancer Research at Newcastle University, and is Past-Chairman of the British Association for Cancer Research and of the Laboratory Research Division of the European Organisation for Research and Treatment of Cancer. Professor Newell was involved in the development of the registered agents carboplatin (Paraplatin) and ralitrexed (Tomudex), and is currently working on the discovery and development of molecularly-targeted anticancer drugs and associated predictive and pharmacological biomarkers. His specific drug discovery research interests include the identification of enzyme and protein-protein interaction inhibitors, using both structural biology and computational chemistry, and their evaluation in pre-clinical tumour models. Imaging techniques where Professor Newell has research interests include both pre-clinical and clinical Positron Emission Tomography (PET) and Nuclear Magnetic Resonance (NMR) spectroscopy and imaging. He is an author of over 200 scientific articles and an Editor-in-Chief of the journal Cancer Chemotherapy and Pharmacology. In addition to his academic work, Professor Newell has consulted widely for both pharmaceutical and biotechnology companies. In 2011, Professor Newell was elected to the Academy of Medical Sciences.